Very good question RY,
For ATL1102 and DMD...there are only 2 or maybe 3 partnerships investors would be keen to see
Sarepta, Roche and maybe Ionis if they want to bring ATL1102 back to the stable with their renewed strategy of commercializing their own product lines.
Given Sarepta's gene tech delays and Exondys issues with FDA....they would be standout partner for US trial.
Exciting times - time will tell.
Ann: Trading Halt, page-30
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
8.1¢ |
Change
0.002(2.53%) |
Mkt cap ! $85.85M | |||
| Open | High | Low | Value | Volume |
| 8.0¢ | 8.1¢ | 7.9¢ | $110.7K | 1.388M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 552412 | 7.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.1¢ | 217684 | 2 |
View Market Depth
| Last trade - 16.10pm 18/11/2024 (20 minute delay) ? |
| PER (ASX) Chart |